RECORD // Company

Cadrenal Therapeutics, Inc.

Built 2026-11-21T11:42:46Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001213900-26-120837

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-1,246,8713 months ended 2026-09-3010-Q2026-11-160001213900-26-1208372026-11-21 11:42 UTCReport an error
Cash and cash equivalents$3,056,086at 2026-09-3010-Q2026-11-160001213900-26-1208372026-11-21 11:42 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001937993
Ticker
CVKD
EIN
880860746
CUSIP
127636207
Record ID
sx:sec:0001937993

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-17SEC EDGAR company profile2026-11-21 11:42 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-17SEC EDGAR company profile2026-11-21 11:42 UTCReport an error
State of incorporationDE2026-11-17SEC EDGAR company profile2026-11-21 11:42 UTCReport an error
Fiscal year end (MMDD)12312026-11-17SEC EDGAR company profile2026-11-21 11:42 UTCReport an error
Business address822 A1A NORTH, SUITE 306, PONTE VEDRA, FL, 320822026-11-17SEC EDGAR company profile2026-11-21 11:42 UTCReport an error
ExchangesNasdaq2026-11-17SEC EDGAR company profile2026-11-21 11:42 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-13,237,3622025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:42 UTCReport an error
Total assets (at 2025-12-31)$4,326,7082025-12-3110-K, XBRL Assets2026-11-21 11:42 UTCReport an error
Stockholders' equity (at 2025-12-31)$2,738,7262025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:42 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$4,007,7892025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:42 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-12,601,6662025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:42 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$5,1042025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:42 UTCReport an error
Form D total offering amount (D filed 2026-07-15)$8,843,8492026-07-15D2026-11-21 11:42 UTCReport an error
Form D total amount sold (D filed 2026-07-15)$8,843,8492026-07-15D2026-11-21 11:42 UTCReport an error
Form D industry groupBiotechnology2026-07-15D2026-11-21 11:42 UTCReport an error
Form D revenue rangeDecline to Disclose2026-07-15D2026-11-21 11:42 UTCReport an error
Form D date of first sale2026-06-302026-07-15D2026-11-21 11:42 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-07)On October 7, 2026, the Company issued a press release announcing that its Board of Directors has authorized the Company to initiate a formal strategic process to evaluate opportunities to maximize the value of the Company and its asset portfolio. Potential opportunities may include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, or other strategic transactions. The strategic review is at a preliminary stage, and the Company has not set a deadline or definitive timetable for the completion of the process. There can be no assurance that the strategic process will result in any transaction or other…2026-10-07SEC EDGAR 8-K 0001213900-26-107442 (text as filed, excerpt)2026-11-21 11:42 UTCReport an error
8-K Item 5.02, Departure of Directors or Certain (filed 2026-09-29)Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amendment to 2022 Successor Equity Incentive Plan On September 24, 2026, Cadrenal Therapeutics, Inc. (the “Company”), held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). At the 2026 Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment No. 2”) to the Company’s 2022 Successor Equity Incentive Plan, as amended (the “2022 Plan”), to increase the number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), that will be available for awards under the 2022 Plan by 323,542 shares to 1,000,000 shares. A…2026-09-29SEC EDGAR 8-K 0001213900-26-104647 (text as filed, excerpt)2026-11-21 11:42 UTCReport an error
8-K Item 5.07, Submission of Matters to a Vote of Security Holders (filed 2026-09-29)On September 24, 2026, the Company held its 2026 Annual Meeting at which the Company’s stockholders voted on the following five (5) proposals and cast their votes as described below. These matters are described in detail in the Proxy Statement. As of July 27, 2026, the record date for the 2026 Annual Meeting, there were 3,567,592 shares of Common Stock outstanding and entitled to vote at the 2026 Annual Meeting. Present in person or by proxy at the 2026 Annual Meeting were 2,155,341 shares of Common Stock, which constituted a quorum. The final voting results for each item of business voted upon at the 2026 Annual Meeting, as described in the Proxy Statement, is set forth below. Proposal 1.…2026-09-29SEC EDGAR 8-K 0001213900-26-104647 (text as filed, excerpt)2026-11-21 11:42 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-31)On August 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) issued a press release announcing positive feedback from a Type D Meeting with the U.S. Food and Drug Administration (“FDA”) held on July 28, 2026. During the meeting, the Company and the FDA aligned on key aspects of the protocol and Statistical Analysis Plan for a Phase 3 registrational study of CAD-1005, the Company’s first-in-class 12-lipoxygenase (“12-LOX”) inhibitor in development to treat heparin-induced thrombocytopenia (“HIT”). During the Type D meeting, the FDA agreed on an optimized definition of worsening HIT for the primary endpoint, based on progression of thrombotic events through Day 14 of treatment or hospital…2026-08-31SEC EDGAR 8-K 0001213900-26-095394 (text as filed, excerpt)2026-11-21 11:42 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-08-31)On August 31, 2026, the Company issued a press release announcing positive feedback from a Type D Meeting with the FDA held on July 28, 2026. During the meeting, the Company and the FDA aligned on key aspects of the protocol and Statistical Analysis Plan for a Phase 3 registrational study of CAD-1005, the Company’s first-in-class 12-LOX inhibitor in development to treat HIT. During the Type D meeting, the FDA agreed on an optimized definition of worsening HIT for the primary endpoint, based on progression of thrombotic events through Day 14 of treatment or hospital discharge. To ensure high-quality, reliable endpoint evaluation across clinical sites, the worsening component of the primary…2026-08-31SEC EDGAR 8-K 0001213900-26-095394 (text as filed, excerpt)2026-11-21 11:42 UTCReport an error
8-K Item 2.02, Results of Operations and Financial (filed 2026-08-13)Condition. On August 13, 2026, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in…2026-08-13SEC EDGAR 8-K 0001213900-26-089147 (text as filed, excerpt)2026-11-21 11:42 UTCReport an error
Largest institutional holder #1 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$167,4582026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:42 UTCReport an error
Largest institutional holder #2 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$63,5402026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:42 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD FIDUCIARY TRUST CO$27,7592026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:42 UTCReport an error
Largest institutional holder #4 (13F as filed): Tower Research Capital LLC (TRC)$4,2822026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:42 UTCReport an error
Largest institutional holder #5 (13F as filed): UBS Group AG$3,7142026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:42 UTCReport an error
Largest institutional holder #6 (13F as filed): Grove Bank & Trust$3,3402026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:42 UTCReport an error
Largest institutional holder #7 (13F as filed): Clearstead Advisors, LLC$2,1712026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:42 UTCReport an error
Largest institutional holder #8 (13F as filed): Quest 10 Wealth Builders, Inc.$1,2692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:42 UTCReport an error
Largest institutional holder #9 (13F as filed): OSAIC HOLDINGS, INC.$1,0022026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:42 UTCReport an error
Largest institutional holder #10 (13F as filed): Rockefeller Capital Management L.P.$5012026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:42 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.